{"id":7235,"date":"2013-06-05T03:02:52","date_gmt":"2013-06-05T07:02:52","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7235"},"modified":"2013-06-05T03:02:52","modified_gmt":"2013-06-05T07:02:52","slug":"novogen-limited-adr-nasdaqnvgns-primary-focus-on-research","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235","title":{"rendered":"Novogen Limited ADR (NASDAQ:NVGN)&#8217;s primary focus on research"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The shares of Novogen Limited ADR (NASDAQ:NVGN), engaged in consumer health care products had surged by 30.26 percent to close at $5.08 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $3.90 to $5.50 per share during the day. The shares of Novogen Limited ADR (NASDAQ:NVGN) had recorded 52 week high price level of $10.49 per share and 52 week low price level of $1.47 per share.<\/p>\n<p style=\"text-align: justify;\">Novogen Limited ADR (NASDAQ:NVGN) had recently issued ordinary shares at a price of AUD 0.166 per share to facilitate the funding of company\u2019s Phase 1 of CS 6 program, working capital requirements and other corporate costs. Novogen Limited ADR (NASDAQ:NVGN) is primarily focused on pharmaceutical research and development, manufacturing and commercialization of consumer health care products. The company operates its business in three basic segments namely Consumer Business and Wound Healing, Drug Development and Oncology Drug Program.<\/p>\n<p style=\"text-align: justify;\">The shares of Novogen Limited ADR (NASDAQ:NVGN) had recently been surging in their prices and had been experiencing heavy trading volumes in the market. The pharmaceutical research and development company had experienced the trade of nearly 335,341 shares on the last trading session on Tuesday, while the average trading volume of Novogen Limited ADR (NASDAQ:NVGN) is at 30,009 shares per day.<\/p>\n<p style=\"text-align: justify;\">Novogen Limited ADR (NASDAQ:NVGN) presently holds 6.79 million shares outstanding in the market and the institutional ownership in the company is at 1 percent of its holdings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The shares of Novogen Limited ADR (NASDAQ:NVGN), engaged in consumer health care products had surged by 30.26 percent to close at [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7236,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2459,2458],"stock_ticker":[],"class_list":["post-7235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqnvgn","tag-novogen-limited-adr-nasdaqnvgn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novogen Limited ADR (NASDAQ:NVGN)&#039;s primary focus on research - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novogen Limited ADR (NASDAQ:NVGN)&#039;s primary focus on research - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The shares of Novogen Limited ADR (NASDAQ:NVGN), engaged in consumer health care products had surged by 30.26 percent to close at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-05T07:02:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Novogen Limited ADR (NASDAQ:NVGN)&#8217;s primary focus on research\",\"datePublished\":\"2013-06-05T07:02:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg\",\"keywords\":[\"NASDAQ:NVGN\",\"Novogen Limited ADR (NASDAQ:NVGN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\",\"name\":\"Novogen Limited ADR (NASDAQ:NVGN)'s primary focus on research - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg\",\"datePublished\":\"2013-06-05T07:02:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novogen Limited ADR (NASDAQ:NVGN)&#8217;s primary focus on research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novogen Limited ADR (NASDAQ:NVGN)'s primary focus on research - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235","og_locale":"en_US","og_type":"article","og_title":"Novogen Limited ADR (NASDAQ:NVGN)'s primary focus on research - Wall Street PR","og_description":"Boston, MA 06\/05\/2013 (wallstreetpr) &#8211;\u00a0The shares of Novogen Limited ADR (NASDAQ:NVGN), engaged in consumer health care products had surged by 30.26 percent to close at [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-05T07:02:52+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Novogen Limited ADR (NASDAQ:NVGN)&#8217;s primary focus on research","datePublished":"2013-06-05T07:02:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg","keywords":["NASDAQ:NVGN","Novogen Limited ADR (NASDAQ:NVGN)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235","url":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235","name":"Novogen Limited ADR (NASDAQ:NVGN)'s primary focus on research - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg","datePublished":"2013-06-05T07:02:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-1.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/novogen-limited-adr-nasdaqnvgns-primary-focus-on-research-7235#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Novogen Limited ADR (NASDAQ:NVGN)&#8217;s primary focus on research"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7235"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7235\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7236"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7235"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}